Zealand announces results of a Phase II Proof-of-Concept trial with danegaptide for cardiac reperfusion injuries
March 02, 2016 11:49 ET
|
Zealand Pharma A/S
Danegaptide did not meet the primary efficacy endpoint of reducing ischemic reperfusion injuries, measured on the Myocardial Salvage Index, in patients with an ST-elevation myocardial infarction...
Zealand offentliggør resultater fra et fase II “Proof-of-Concept”-studie med danegaptid mod reperfusionsskader i hjertet
March 02, 2016 11:49 ET
|
Zealand Pharma A/S
Danegaptid opfyldte ikke det primære effektmål om at reducere reperfusionsskader, målt som et indekstal for beskyttelse af hjertevæv, hos patienter med ST-elevationsmyokardieinfarkt, som fik...
Zealand præsenterer på fire internationale biotek/healthcare-investorkonferencer i marts og april 2016
February 26, 2016 09:22 ET
|
Zealand Pharma A/S
København, 26. februar 2016 – Zealand meddeler, at selskabets ledelse vil præsentere selskabet og afholde investormøder ved følgende healthcare- og biotek-investorbegivenheder, der afholdes i marts...
Zealand presents at four international biotech/healthcare investor conferences in March and April 2016
February 26, 2016 09:22 ET
|
Zealand Pharma A/S
Copenhagen, 26 February 2016 – Zealand informs that its management will present the company and host investor meetings at the following healthcare and biotech investor forums in March and April...
Zealand announces that Sanofi’s NDA for the fixed-ratio combination (LixiLan) of lixisenatide and insulin glargine for Type 2 diabetes has been accepted for review by the FDA
February 22, 2016 01:12 ET
|
Zealand Pharma A/S
FDA’s acceptance includes Sanofi’s redemption of a Priority Review Voucher with the NDA filing
Based on a six months priority review process, a US regulatory decision is expected in August...
Zealand meddeler, at Sanofis registreringsansøgning for præmix-kombinationen (LixiLan) af lixisenatid og insulin glargin til type 2-diabetes er blevet accepteret af FDA
February 22, 2016 01:12 ET
|
Zealand Pharma A/S
FDA’s accept omfatter den prioritetskupon, Sanofi har indløst som en del af registreringsansøgningen
Med udgangspunkt i den forkortede behandlingstid på seks måneder forventes en...
Notice of the date for Zealand’s Annual General Meeting 2016 and of deadline for proposals to the agenda
February 18, 2016 05:13 ET
|
Zealand Pharma A/S
Copenhagen, 18 February 2016 – Zealand informs that its Annual General Meeting for 2016 will be held on
Tuesday, 19 April 2016 at 1.30 pm
at
Plesner Law Firm,
Amerika Plads 37,
2100...
Zealand meddeler datoen for sin ordinære generalforsamling 2016 samt frist for forslag til dagsordenen
February 18, 2016 05:13 ET
|
Zealand Pharma A/S
København, 18. februar 2016 – Zealand meddeler, at selskabets ordinære generalforsamling for 2016 vil blive afholdt
Tirsdag, 19. april kl. 13.30
hos
Plesner advokatfirma,
Amerika Plads...
Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016
February 15, 2016 02:32 ET
|
Zealand Pharma A/S
• ZP1848 is a long-acting GLP-2 analogue having shown attractive potential as a new therapy in short bowel syndrome, a specialty disease of high unmet medical needs
• Earlier in...
Zealand doserer de første patienter med ZP1848 mod korttarmssyndrom og tager dermed det andet af sine egne speciallægemidler videre til fase II-udvikling i 2016
February 15, 2016 02:32 ET
|
Zealand Pharma A/S
• ZP1848 er en langtidsvirkende GLP-2-analog, som har vist attraktivt potentiale som en ny behandling af korttarmssyndrom, der er en specialsygdom med et stort udækket behandlingsbehov
• Tidligere...